P53 Expression in Endometrial Hyperplasia and Endometrial Carcinoma
DOI:
https://doi.org/10.15218/zjms.2010.019Keywords:
Endometrial carcinoma, endometrial hyperplasia, p53geneAbstract
Background and objective: Mutations of the P53 tumor suppressor gene and altera-tions in its protein expression often occur in a variety of human malignant tumors, including endometrial carcinoma, but the practical implications of this phenomenon are yet to be fully exploited. This study was designed to evaluate P53 protein expression in normal, hyper-plastic and malignant endometrium by immunohistochemical study and to correlate P53 expression in endometrial carcinoma with other clinic-pathological prognostic parameters (age, histologic type, tumor grade, cervical & myometrial invasion, and tumor stage).
Methods: The studied samples included 100 formalin fixed, paraffin embedded endo-metrial tissue specimens which were divided to the following diagnostic categories: - Pro-liferative endometrium (n=10); secretory endometrium (n=10); simple hyperplasia (n=10); complex hyperplasia without atypia (n=20); atypical complex hyperplasia (n=10) and endo-metrial carcinoma (n=40).
Results: None of the normal endometrium, simple hyperplasia and complex hyperplasia without atypia showed P53 immunostaining, while 20% of atypical complex hyperplasia and 32.5% of endometrial carcinoma showed immunoreactivity for P53. In endometrial car-cinoma, significant correlation was observed between P53 expression and age at diagno-sis, histological grade,FIGO stage, myometrial invasion & cervical invasion ; but not with the histological type .
Conclusion: The results indicated the validity & simplicity of the application of immuno-histochemistry in determining the status of P53 overexpresion which is strongly associated with endometrial carcinoma aggressiveness and high malignant potential.
Metrics
References
Horn LC, Meinel A, Handzel R. Histopathology of endometrial hyperplasia and endometrial carci-noma. An update. Ann Diagn Pathol 2007; 11:297-311.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
Munstedt K, Grant P, Joachim W, Roth G, Tinne-berg H-R. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg oncol 2004; 2:24-30.
Bartels PH, Garcia FA, Davis J, Silva VD, Bartels HG,Thompson D, et al . Progression curves for endometrial lesions. Analyt Quant Cytol Histol 2001; 23(1):1-8.
Fernando SE, Wu X, Perera LS. P53 overexpres-sion and steroid hormone receptor status in en-dometrial carcinoma. Int J Surg Pathol 2000; 8:213-222.
Etebary M, Jahanzad I, Mohagheghi MA, Azizi E.Immunohistochemical anyalysis of p53 and its correlation to the other prognostic factors in breast cancer. Acta Medica Iranica 2002; 40(2):88-94.
Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351:453-456.
Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB . Interpretation of p53 immunoreac-tivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23:129-137.
Sredni ST, Zerbin MCN, Latorre MR, Alves VAF. P53 as a prognostic factor in adrenocortical tu-mors of adults and children. Braz J Med Biol Res 2003; 36:23-27.
Lane DP.Cancer.P53, guardian of the genome. Nature 1992;358:15-16.
Pierre M, Evelyne M. Twenty years on p53 re-search : Structural and functional aspects of the p53 protein. Oncogen 1999; 18:621-636.
Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27:1050-1055.
Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998 ; 29:613-619.
Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M . Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinoma expressing p53 protein. Histopathology 1998; 33:440-445.
Lax SF, Kendall B, Tashiro H , Slebos RJ, Hed-rick L. The frequency of K-ras mutations and microsatellite instability differs in uterine endo-metrioid and serous carcinoma: Evidence of dis-tinct molecular genetic pathways. Cancer 2000; 26:814-824.
Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating func-tional and non- functional p53 in human tumors by p53 and MDM2 immunohistochemistry. J Pathol. 2005;207: 251-259.
Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium. Mol Vis. 2005; 11: 50-55.
Elhafey AS, Papadimitriou JC, El-Hakim MS, El-Said AI. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplasitc, and malignant endo-metrium. Arch Pathol Lab Med 2001; 125:872-879.
Sakuragi N, Salah-eldin A, Watari H, Itoh T, Inoue S, Moriuchi T, et al. Bax, bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol 2002; 86:288-296.
Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW . Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13(4):379-388.
Veral A, Zekioglu O, Nart D, Ciris M, Ozdemir N, Erhan Y. P53, ERB, KI67, estrogen and proges-terone receptor expression and histological pa-rameters in type I and type II endometrial carci-noma. Ann Saudi Med 2002; 22:242-243.
Erdem O, Erdem M, Dursun A, Akyol G, Erdem A. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: Comparison with traditional clinicopathologic variables. Int J Gynecol Pathol 2003; 22(3):254-260.
Egan JA, Ionescu MC, Eapan E, Jones JG, Mar-shall DS. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23:119-122.
Jeon Y-T, Kang S, Kang K-H, Yoo K-Y, Park I-A, Bang Y-J, et al. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(9):1538-1541.
Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. P53 expression as a prognostic indicator of 5-year survival in endo-metrial cancer. Gynecol Oncol 1999; 74:468-471.
Ragni N, Ferrero S, Prefumo F, Muschiato B, Gorlero F, Gualco M, et al. The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2005; 123:111-116.
Nielsen AL, Nyholm HC. P53 and c-erb-2 protein expression in endometrial adenocarcinoma of endometrioid type. Am J Clin Pathol 1994; 102:76-79.
Maeda K, Tsuda H, Hashiguchi Y, Yamamoto K, Inoue T, Ishiko O, et al. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002; 33:386-391.
Kohlberger P, Gitsch G, Loesch A, Tempfer C, Kaider A, Reinthaller A, et al. P53 protein over expression in early stage endometrial cancer. Gynecol Oncol 1996; 62:213-217.
Gassel AM, Backe J, Krebs S, Schon S, Caffier H, Muller-Hermelink HK. Endometrial carci-noma: Immunohistochemically detected prolif-eration index is a prognosticator of long term outcome. J Clin Pathol 1998; 51:25-29.
Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ , et al. Prognostic value of p53 and proliferating nuclear antigen expres-sion in endometrial carcinoma. Gynecol Oncol 1996; 62:192-198.
Ohkouchi T, Sakuragi N, Watari H, Nomura E, Todo Y, Yamada H, et al. Prognostic signifi-cance of bcl-2, p53 over expression, and lymph node metastasis in surgically staged endo-metrial carcinoma. Am J Obstet Gynecol 2002; 187(2):353-359.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2010 Nadya Y. Ahmed, Rivan Hermiz Isaac (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
